Scholars Central

Research articlePublished 2013

Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity

Authors: Roberto Angioli, Michela Angelucci, Francesco Plotti, Corrado Terranova, Roberto Montera, Patrizio Damiani, Ester Valentina Cafa, Pierluigi Benedetti Panici, Angiolo Gadducci

Chemotherapy: Open Access

Volume 2 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Pegylated liposomal doxorubicin (PLD) is considered to be the single-agent of first choice for patients with recurrent ovarian cancer following paclitaxel/carboplatin-based chemotherapy. However, this drug is associated with a local inflammatory tissue reaction, called palmoplantar erythrodysesthesia (PPE). A new liposomal formulation, known as Liposome Encapsulated Doxorubicin Citrate (LEDC), has been developed in the past decades to limit PPE. In this study we report our experience with LEDC in patients with recurrent ovarian cancer who discontinued doxil due to severe PPE. Methods: The present retrospective study included 43 patients with recurrent ovarian cancer who were treated with LEDC administered at the dose of 50 mg/mq every 3 weeks until disease progression or unacceptable toxicity. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria Version 3. Response was graded according to Response Evaluation Criteria in Solid Tumors (RECIST). Results: A total of 32 patients completed planned 6 cycles of chemotherapy. A complete response was achieved in 6%, partial response in 20%, stable disease in 37% and progression in 9% of patients. No cutaneous toxicity was reported. Conclusion: LEDC is a well tolerated drug and a valid therapeutic option for patients with ovarian cancer suffering from doxil-related cutaneous toxicity.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Chemotherapy: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalChemotherapy: Open Access
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Roberto Angioli”
  • BylineArticles whose byline prints “Michela Angelucci”
  • BylineArticles whose byline prints “Francesco Plotti”
  • BylineArticles whose byline prints “Corrado Terranova”
  • BylineArticles whose byline prints “Roberto Montera”
  • BylineArticles whose byline prints “Patrizio Damiani”
  • BylineArticles whose byline prints “Ester Valentina Cafa”
  • BylineArticles whose byline prints “Pierluigi Benedetti Panici”